ConductScience.org, home

Paper39771997

Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.

Wang J and 5 others. Vaccines (Basel), 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review. Papers, record 39771997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39771997

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.
PubMed
Journal
Vaccines (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.67, provisional
iCite
Revised in PubMed
2026-09-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang JJiao
2Zhao ZZianhttps://orcid.org/0009-0001-2376-5298
3Wang QQuan
4Shi JJingyuhttps://orcid.org/0000-0001-7650-8212
5Wong DWDuo Wai-Chihttps://orcid.org/0000-0002-8805-1157
6Cheung JCJames Chung-Waihttps://orcid.org/0000-0001-7446-0569

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References161

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132992617The Importance of Evaluating the Lot-to-Lot Batch Consistency of Commercial Multi-Walled Carbon Nanotube Products.Nanomaterials (Basel)2020https://conductscience.org/library/papers/32992617PubMed
220822351Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.Expert Rev Vaccines2010https://conductscience.org/library/papers/20822351PubMed
333249249Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery.Int J Pharm2021https://conductscience.org/library/papers/33249249PubMed
433529034Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Streptococcus Vaccine Delivery.J Med Chem2021https://conductscience.org/library/papers/33529034PubMed
529983563Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.Int J Nanomedicine2018https://conductscience.org/library/papers/29983563PubMed
628943194Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles.J Control Release2017https://conductscience.org/library/papers/28943194PubMed
737111723Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity.Pharmaceutics2023https://conductscience.org/library/papers/37111723PubMed
823657437Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery.Nanoscale2013https://conductscience.org/library/papers/23657437PubMed
915628980Protective effect of neonatal BCG vaccines against tuberculous meningitis.Bosn J Basic Med Sci2004https://conductscience.org/library/papers/15628980PubMed
1038164481Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants as prophylactic vaccine after nasal administration in mice.Iran J Basic Med Sci2024https://conductscience.org/library/papers/38164481PubMed
1133811104Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses.J Immunol2021https://conductscience.org/library/papers/33811104PubMed
1231260754Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles.J Control Release2019https://conductscience.org/library/papers/31260754PubMed
1331579445Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration.Iran J Basic Med Sci2019https://conductscience.org/library/papers/31579445PubMed
1431089379Formulation and Optimization of a New Cationic Lipid-Modified PLGA Nanoparticle as Delivery System for Mycobacterium tuberculosis HspX/EsxS Fusion Protein: An Experimental Design.Iran J Pharm Res2019https://conductscience.org/library/papers/31089379PubMed
1524248387Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/24248387PubMed
1630733717Nanoparticle-Based Vaccines Against Respiratory Viruses.Front Immunol2019https://conductscience.org/library/papers/30733717PubMed
1722328935Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine.PLoS One2012https://conductscience.org/library/papers/22328935PubMed
1834264684Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines.Mol Pharm2021https://conductscience.org/library/papers/34264684PubMed
1920934457Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation.Vaccine2010https://conductscience.org/library/papers/20934457PubMed
2032206497Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.3 Biotech2020https://conductscience.org/library/papers/32206497PubMed

See all 161 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42963803Current strategies and challenges in vaccine platforms for Newcastle Disease Virus.Trop Dis Travel Med Vaccines2026https://conductscience.org/library/papers/42963803PubMed
42220545Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review.Front Immunol2026https://conductscience.org/library/papers/42220545PubMed
41770791A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold.PLoS Pathog2026https://conductscience.org/library/papers/41770791PubMed
41746080Advances in Nanoparticles as Vaccine Adjuvants.Vaccines (Basel)2026https://conductscience.org/library/papers/41746080PubMed
41304797Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance.Pharmaceutics2025https://conductscience.org/library/papers/41304797PubMed
40629425Chitosan-based formulations for therapeutic applications. A recent overview.J Biomed Sci2025https://conductscience.org/library/papers/40629425PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39771997

GET https://conductscience.org/api/papers/v1/39771997/references?page=2